You just read:

Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

News provided by

Nektar Therapeutics

Nov 09, 2016, 14:30 ET